Detalhe da pesquisa
1.
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
Lancet Oncol
; 24(3): 228-238, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36858721
2.
A phase 1b study of the allosteric extracellular FGFR2 inhibitor alofanib in patients with pretreated advanced gastric cancer.
Invest New Drugs
; 41(2): 324-332, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36907947
3.
Patterns of Care and Barriers to Utilization of Definitive Concurrent Chemoradiation Therapy for Stage III Non-Small Cell Lung Cancer in Russia.
J Cancer Educ
; 37(5): 1378-1384, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33533013
4.
Management of Muscle Invasive Bladder Cancer with Bladder Preservation in Russia: a Survey-Based Analysis of Current Practice and the Impact of an Educational Workshop on Clinical Expertise.
J Cancer Educ
; 36(5): 1005-1013, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32130672
5.
Radiotherapy for Hepatocellular Carcinoma in Russia: a Survey-Based Analysis of Current Practice and the Impact of an Educational Workshop on Clinical Expertise.
J Cancer Educ
; 35(1): 105-111, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30467774
6.
Efficacy and safety of RGB-02, a pegfilgrastim biosimilar to prevent chemotherapy-induced neutropenia: results of a randomized, double-blind phase III clinical study vs. reference pegfilgrastim in patients with breast cancer receiving chemotherapy.
BMC Cancer
; 19(1): 122, 2019 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30727980
7.
Bridging the Gap in Global Advanced Radiation Oncology Training: Impact of a Web-Based Open-Access Interactive Three-Dimensional Contouring Atlas on Radiation Oncologist Practice in Russia.
J Cancer Educ
; 34(5): 871-873, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-29938298
8.
Tamoxifen Never Ceases to Amaze: New Findings on Non-Estrogen Receptor Molecular Targets and Mediated Effects.
Cancer Invest
; 36(4): 211-220, 2018 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-29727200
9.
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 18(11): 1467-1482, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28958504
10.
Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.
Invest New Drugs
; 35(2): 127-133, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27812884
11.
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
N Engl J Med
; 369(18): 1691-703, 2013 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-24131140
12.
Preoperative chemotherapy in patients with resectable esophageal carcinoma: a single center Phase II study.
Jpn J Clin Oncol
; 46(7): 610-4, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27052115
13.
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.
Lancet Oncol
; 15(6): 569-79, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24739896
14.
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Lancet Oncol
; 15(6): 640-7, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24657003
15.
First-line checkpoint inhibitors in PD-L1-positive patients with advanced urothelial carcinoma.
BJU Int
; 123(4): 563-565, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30457694
16.
Prognostic and predictive role of immune microenvironment in colorectal cancer.
World J Gastrointest Oncol
; 16(3): 643-652, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38577454
17.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
J Clin Oncol
; 42(11): 1222-1228, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38227898
18.
Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer.
Oncologist
; 17(4): 469-75, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22467666
19.
A phase II multicenter study of two different dosages of pemetrexed given in combination with cyclophosphamide as first-line treatment in patients with locally advanced or metastatic breast cancer.
Cancer Invest
; 30(4): 309-16, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-22468806
20.
Randomized, Double-Blind, Placebo-Controlled Phase III Study of Paclitaxel ± Napabucasin in Pretreated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Clin Cancer Res
; : OF1-OF9, 2022 Jul 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35833783